Egbert Smit

Leiden University Medical Center

Netherlands

Research Interests

Explore related searches

Professors in Netherlands Professors in Immunology Immunology professors in Netherlands

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (6)

Gerrit Meijer

Professor of Oncologic Pathology

University Medical Center Groningen

NETHERLANDS

View details

Koen Hartemink

Prof. dr.

Universitair Medisch Centrum Utrecht

NETHERLANDS

View details

Michel M. van den Heuvel

Radboud University Medical Center

NETHERLANDS

View details

Kim Monkhorst

The Netherlands Cancer Institute

NETHERLANDS

View details

Henk-Jan Guchelaar

Leiden University Medical Center

NETHERLANDS

View details

Tijmen van der Wel

Leiden University Medical Center

NETHERLANDS

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Egbert Smit

Research Interests

Explore related searches

Contact this professor

Articles (10)

Interstitial lung disease epidemiology and etiology in patients with solid malignant tumors: a systematic literature review

Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis

Body Weight Gain Associated With Alectinib in Patients With ALK+ Non–Small Cell Lung Cancer: Pooled Analysis of Individual Patient Data From Four Prospective Clinical Trials

Analytical and Clinical Validation of the Plasma-Based Guardant360 CDx Test for Assessing HER2 (ERBB2) Mutation Status in Patients with Non–Small-Cell Lung Cancer for Treatment with Trastuzumab Deruxtecan in DESTINY-Lung01/02

Model-Informed Development of a Cost-Saving Dosing Regimen for Sacituzumab Govitecan

Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer

Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol

Survival difference between patients with single versus multiple metastatic lymph nodes and the role of histology in pathological stage II-N1 non-small cell lung cancer

Author Correction: BRAFV600E-mutant metastatic NSCLC: disease overview and treatment landscape

BRAFV600E-mutant metastatic NSCLC: disease overview and treatment landscape

Collaborators (6)

Gerrit Meijer

Koen Hartemink

Michel M. van den Heuvel

Kim Monkhorst

Henk-Jan Guchelaar

Tijmen van der Wel

Make your next move.